Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
238.64
-1.35 (-0.56%)
At close: Feb 9, 2026, 4:00 PM EST
239.04
+0.40 (0.17%)
After-hours: Feb 9, 2026, 7:59 PM EST
Johnson & Johnson Revenue
In the year 2025, Johnson & Johnson had annual revenue of $94.19B with 6.05% growth. Johnson & Johnson had revenue of $24.56B in the quarter ending December 31, 2025, with 9.08% growth.
Revenue (ttm)
$94.19B
Revenue Growth
+6.05%
P/S Ratio
6.15
Revenue / Employee
$682,064
Employees
138,100
Market Cap
574.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.19B | 5.37B | 6.05% |
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
JNJ News
- 10 hours ago - Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference - Business Wire
- 3 days ago - Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium - Business Wire
- 5 days ago - These hot S&P 500 stocks show where investors are heading as they run away from tech - Market Watch
- 6 days ago - What's Behind The 50% Surge In JNJ Stock? - Forbes
- 7 days ago - Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland - GlobeNewsWire
- 7 days ago - Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference - Business Wire
- 8 days ago - Ariel Focus Fund Q4 2025 Portfolio Review - Seeking Alpha
- 10 days ago - Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over - Seeking Alpha